Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Lübbert, Michael
  • Schmoor, Claudia
  • Berg, Tobias
  • Kruszewski, Michael
  • Schittenhelm, Marcus Matthias
  • Götze, Katharina
  • Pabst, Caroline
  • Kündgen, Andrea
  • Ma, Tobias
  • Frey, Anna
  • Moschallski, Kevin
  • Rehman, Usama-Ur
  • Jung, Johannes
  • Duyster, Justus
  • Jung, Manfred
  • Schüle, Roland
  • Wäsch, Ralph
  • Grishina, Olga

publication date

  • November 15, 2022

published in